SEC Filing Summary: Harvard Bioscience Inc. (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harvard Bioscience, Inc. on September 23, 2002. The report pertains to the filing of a prospectus supplement dated September 23, 2002, which amends a prospectus originally dated September 17, 2002, pursuant to Rule 424(b)(3) and (c) under the Securities Act of 1933.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of a regulatory filing rather than a financial performance update.
Material Changes
No material changes to financial performance or operations are reported in this document. The primary event is the submission of the aforementioned prospectus supplement.
Guidance, Outlook, and Risks
The filing contains a standard disclaimer regarding forward-looking statements, noting that actual results may differ materially from anticipated results due to known and unknown risks. The document refers investors to the "Important Factors That May Affect Future Operating Results" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2001, for detailed risk factors. The Company explicitly disclaims any obligation to update forward-looking statements.
Key Facts for Investor Verification
- Verify the contents of the attached Prospectus Supplement (Exhibit 99.1) to understand the specific terms of the offering.
- Review the original prospectus dated September 17, 2002, to compare changes made in the supplement.
- Consult the Form 10-K for the year ended December 31, 2001, for comprehensive risk factors and historical financial data.
- Note that this 8-K does not contain new financial statements or pro forma information.